Skip to main content
    O

    Oric Pharmaceuticals Inc (ORIC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.52
    -0.34 (-4.33%)

    Market Cap: $814.71M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Oric Pharmaceuticals Inc (ORIC) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Oric Pharmaceuticals are Olema Pharmaceuticals (OLMA), Corvus Pharmaceuticals (CRVS) and Kura Oncology (KURA). By market cap, Oric Pharmaceuticals ranks 7th of the 13 companies on this page; Ocular Therapeutix (OCUL) is the largest at $1.37B.

    Peer Comparison

    ORIC's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Oric Pharmaceuticals (ORIC)$814.71MN/AN/A0.0%N/A0.0%0.00%
    Olema Pharmaceuticals Inc (OLMA)$662.30MN/AN/A0.0%-53.8%0.0%0.00%
    Corvus Pharmaceuticals Inc (CRVS)$897.52MN/AN/A0.0%N/A0.0%0.00%
    Kura Oncology Inc (KURA)$713.90MN/A8.0x0.0%-1125.3%10.1%0.00%
    Rigel Pharmaceuticals Inc (RIGL)$837.18M14.2x2.8x106.6%16.7%16.5%0.00%
    Ovid Therapeutics Inc (OVID)$479.38MN/A335.8x0.0%N/A-88.3%0.00%
    Omeros Corporation (OMER)$1.27BN/A16.4x324.9%33.6%14.9%0.00%
    Inhibrx Biosciences, Inc. (INBX)$1.23BN/A610.4x0.0%-66.0%-100.0%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Opus Genetics, Inc. (IRD)$384.68MN/A52.0x0.0%-145.1%-63.1%0.00%
    Ocular Therapeutix Inc (OCUL)$1.37BN/A26.9x0.0%-52.1%-11.5%0.00%
    Geron Corporation (GERN)$622.98MN/A2.9x-22.0%-7.4%27.4%0.00%
    Peer median$775.54M54.6x16.4x0.0%-52.1%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Oric Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Olema Pharmaceuticals Inc (OLMA)
    Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development...
    OLMA competitors
    Corvus Pharmaceuticals Inc (CRVS)
    Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
    CRVS competitors
    Kura Oncology Inc (KURA)
    Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States.
    KURA competitors
    Rigel Pharmaceuticals Inc (RIGL)
    Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases.
    RIGL competitors
    Ovid Therapeutics Inc (OVID)
    Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States.
    OVID competitors
    Omeros Corporation (OMER)
    Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies...
    OMER competitors
    Inhibrx Biosciences, Inc. (INBX)
    Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates.
    INBX competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Opus Genetics, Inc. (IRD)
    Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision.
    IRD competitors
    Ocular Therapeutix Inc (OCUL)
    Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development...
    OCUL competitors
    Geron Corporation (GERN)
    Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic...
    GERN competitors

    Frequently Asked Questions About ORIC

    Who are Oric Pharmaceuticals' main competitors?

    The companies most similar to Oric Pharmaceuticals include Olema Pharmaceuticals (OLMA), Corvus Pharmaceuticals (CRVS), Kura Oncology (KURA), Rigel Pharmaceuticals (RIGL) and Ovid Therapeutics (OVID), listed from the closest match.

    Who is Oric Pharmaceuticals' biggest competitor?

    Ocular Therapeutix (OCUL) is the largest of the similar companies at $1.37B; Olema Pharmaceuticals (OLMA) is the closest match by business profile, size, sector and industry.

    How does ORIC stock compare with its competitors?

    ORIC's net margin is 0.0% against a peer median of 0.0%.

    Which of Oric Pharmaceuticals' competitors pays a higher dividend?

    Oric Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Oric Pharmaceuticals bigger than its competitors?

    No. Oric Pharmaceuticals is 7th by market cap among the 13 companies on this page; the largest is Ocular Therapeutix (OCUL) at $1.37B.